UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.

From migraine to Parkinson’s and obesity, AbbVie is building dominant franchises across multiple high-growth areas. Read why ...

Natco Pharma shares slipped in trade after the company said that the USFDA has issued one (1) observation in the Form-483 for ...